Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02632344 · ClinicalTrials.gov registry record · Phase 2
Pembrolizumab for HPV-associated Recurrent Respiratory Papilloma Patients
A Phase 2 study of Recurrent Respiratory Papillomatosis, sponsored by Massachusetts General Hospital.
- Active
- Registry status
- Phase 2
- Development phase
- 21
- Enrollment target
- 2
- Study locations
NCT02632344 is a Phase 2 study of Recurrent Respiratory Papillomatosis that is active but no longer recruiting, run by Massachusetts General Hospital. The registered enrollment target is 21 participants, below the 35-participant average among 6 other Recurrent Respiratory Papillomatosis trials with a reported enrollment target (40% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT02632344, a Phase 2 study of Recurrent Respiratory Papillomatosis, is active but no longer recruiting, sponsored by Massachusetts General Hospital.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 21 participants
- Enrollment target
- 2
- Study locations
Study Summary
This research study is evaluating an immune modulatory agent as a possible treatment for patients with Recurrent Respiratory Papillomatosis (RRP) with significant disease involving the larynx, trachea, and/or lungs. The investigators will be using Pembrolizumab as the treating agent.
Conditions Studied
Interventions
- DRUG Pembrolizumab
Study Locations (2)
Illinois
- NorthShore University HealthSystem - Evanston
Massachusetts
- Massachusetts General Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2016-04 |
| Est. Completion | 2025-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02632344
The ClinicalTrials.gov registry entry for NCT02632344 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 35-participant average among 6 other Recurrent Respiratory Papillomatosis trials with a reported enrollment target (40% lower). The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Recurrent Respiratory Papillomatosis appearing as the primary indexed condition, and to 1 intervention - of which Pembrolizumab is the first listed.
NCT02632344 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Illinois, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT02632344 about?
NCT02632344 is a clinical study titled "Pembrolizumab for HPV-associated Recurrent Respiratory Papilloma Patients". This research study is evaluating an immune modulatory agent as a possible treatment for patients with Recurrent Respiratory Papillomatosis (RRP) with significant disease involving the larynx, trachea, and/or lungs. The investigators will be using Pembrolizumab as the treating agent.
What is the current status of trial NCT02632344?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 21 participants. The study started on 2016-04. Estimated completion is 2025-12.
What conditions does trial NCT02632344 study?
This clinical trial studies the following conditions: Recurrent Respiratory Papillomatosis.
What interventions are being tested in trial NCT02632344?
The interventions under investigation include: Pembrolizumab (DRUG).
Who is sponsoring clinical trial NCT02632344?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02632344 being conducted?
This trial has 2 study locations across Illinois, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Recurrent Respiratory Papillomatosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Avelumab for People With Recurrent Respiratory Papillomatosis
COMPLETED · Phase 2
-
Zopa Retreatment and Vector Shedding in Adults With RRP
RECRUITING · Phase 4
-
Merck IIT: RRP Pembro and Lenvatinib
RECRUITING · Early Phase 1
-
The Natural History and Biological Study of Pulmonary Recurrent Respiratory Papillomatosis (pRRP)
RECRUITING
-
Autologous Dendritic Cell Vaccine For Recurrent Respiratory Papillomatosis (RRP) Patients
RECRUITING · Phase 1
-
Adjuvant PRGN-2012 in Adult Patients With Recurrent Respiratory Papillomatosis
ACTIVE NOT RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.